## Kuan Hu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6557795/publications.pdf

Version: 2024-02-01

932766 752256 29 487 10 20 citations h-index g-index papers 34 34 34 686 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Upregulation of MiR-205 transcriptionally suppresses SMAD4 and PTEN and contributes to human ovarian cancer progression. Scientific Reports, 2017, 7, 41330.	1.6	65
2	The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer, 2019, 19, 511.	1.1	53
3	HIF1A activates the transcription of IncRNA RAET1K to modulate hypoxia-induced glycolysis in hepatocellular carcinoma cells via miR-100-5p. Cell Death and Disease, 2020, 11, 176.	2.7	49
4	CLEC1B Expression and PD-L1 Expression Predict Clinical Outcome in Hepatocellular Carcinoma with Tumor Hemorrhage. Translational Oncology, 2018, 11, 552-558.	1.7	48
5	Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy?. OncoTargets and Therapy, 2019, Volume 12, 541-548.	1.0	38
6	Perineural invasion as a prognostic factor for intrahepatic cholangiocarcinoma after curative resection and a potential indication for postoperative chemotherapy: a retrospective cohort study. BMC Cancer, 2020, 20, 270.	1.1	22
7	SH3-domain binding protein 1 in the tumor microenvironment promotes hepatocellular carcinoma metastasis through WAVE2 pathway. Oncotarget, 2016, 7, 18356-18370.	0.8	21
8	Investigating effects of preoperative inflammatory biomarkers on predicting survival outcomes of intrahepatic cholangiocarcinoma after curative resection. World Journal of Surgical Oncology, 2020, 18, 272.	0.8	18
9	Integrated analysis of expression, prognostic value and immune infiltration of GSDMs in hepatocellular carcinoma. Aging, 2021, 13, 24117-24135.	1.4	17
10	Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study. Frontiers in Oncology, 2021, 11, 650394.	1.3	16
11	BolA family member 2 enhances cell proliferation and predicts a poor prognosis in hepatocellular carcinoma with tumor hemorrhage. Journal of Cancer, 2019, 10, 4293-4304.	1.2	15
12	Prognostic Value of PLXND1 and TGF- $\hat{l}^2$ 1 Coexpression and Its Correlation With Immune Infiltrates in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 604131.	1.3	13
13	Prognostic Value and Therapeutic Potential of CBX Family Members in Ovarian Cancer. Frontiers in Cell and Developmental Biology, 2022, 10, 832354.	1.8	13
14	Alantolactone: A Natural Plant Extract as a Potential Therapeutic Agent for Cancer. Frontiers in Pharmacology, 2021, 12, 781033.	1.6	12
15	GSDMs are potential therapeutic targets and prognostic biomarkers in clear cell renal cell carcinoma. Aging, 2022, 14, 2758-2774.	1.4	12
16	The novel roles of virus infection-associated gene CDKN1A in chemoresistance and immune infiltration of glioblastoma. Aging, 2021, 13, 6662-6680.	1.4	11
17	Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib. Digestive and Liver Disease, 2019, 51, 1488-1490.	0.4	9
18	Spectrum of Mesenchymal–Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis. Frontiers in Oncology, 2020, 10, 560615.	1.3	8

#	Article	IF	CITATIONS
19	A Comparative Genomic and Phylogenetic Analysis of the Origin and Evolution of the CCN Gene Family. BioMed Research International, 2019, 2019, 1-12.	0.9	6
20	Comprehensive Analysis of YTH Domain Family in Lung Adenocarcinoma: Expression Profile, Association with Prognostic Value, and Immune Infiltration. Disease Markers, 2021, 2021, 1-12.	0.6	6
21	Expression profile and prognostic values of Chromobox family members in human glioblastoma. Aging, 2022, 14, 1910-1931.	1.4	6
22	Hypoxia-induced NIPP1 activation enhances metastatic potential and predicts poor prognosis in hepatocellular carcinoma. Tumor Biology, 2016, 37, 14903-14914.	0.8	5
23	<p>WAVE2 Enhanced Hepatic Stellate Cells Activity in Colorectal Liver Metastases</p> . Cancer Management and Research, 2020, Volume 12, 7671-7680.	0.9	5
24	Dexmedetomidine promotes apoptosis and suppresses proliferation of hepatocellular carcinoma cells via microRNA-130a/EGR1 axis. Cell Death Discovery, 2022, 8, 31.	2.0	5
25	Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment. Aging, 2021, 13, 16541-16566.	1.4	3
26	BTB/POZ domainâ€containing protein 7/hypoxiaâ€inducible factor 1 alpha signalling axis modulates hepatocellular carcinoma metastasis. Clinical and Translational Medicine, 2021, 11, e556.	1.7	3
27	A Pancancer Analysis of the Expression Landscape and Clinical Relevance of Fibroblast Growth Factor Receptor 2 in Human Cancers. Frontiers in Oncology, 2021, 11, 644854.	1.3	2
28	Diverse Chromobox Family Members: Potential Prognostic Biomarkers and Therapeutic Targets in Head and Neck Squamous Cell Carcinoma. International Journal of General Medicine, 2022, Volume 15, 2463-2474.	0.8	2
29	The bioinformatics and experimental analysis of the novel roles of virus infection-associated gene CDC20 for prognosis and immune infiltration in hepatocellular carcinoma. Aging, 0, , .	1.4	0